President, Chief Operating Officer · Sarepta Therapeutics, Inc. (SRPT)

Ian Estepan

A named executive officer of Sarepta Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,444,392

FY2024: $2,752,522

3rd of 6 named executive officers at Sarepta Therapeutics by FY2025 total.

6 named officers on file for Sarepta Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Sarepta Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Sarepta Therapeutics’s whole pay program stands against its peers

  • Sarepta Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SRPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A).

Free

Get Ian Estepan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Ian Estepan and every company like it: Velarion Intel, free for 3 days, no card →

Ian Estepan compensation by year

Sarepta Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Sarepta Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024FY2025
Salary$445,822$525,000$539,842$618,511$656,961$740,529
Bonus$0——$0$0$0
Stock awards$434,986$1,306,650$643,360$701,955$772,020$2,603,966
Option awards$4,058,579$2,959,290$2,263,099$1,988,909$845,250$822,879
Non-equity incentive$205,549$315,000$353,194$365,930$430,206$260,000
Pension and deferred compensation$0——$0$0$0
All other$32,744$21,745$24,494$30,321$48,085$17,019
Total$5,177,681$5,127,685$3,823,989$3,705,626$2,752,522$4,444,392

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177247, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sarepta Therapeutics, Inc. filed document, accession 0001193125-26-177247. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$5.2M
$5.1M
$3.8M
$3.7M
$2.8M
$4.4M
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU93,875$2,020,190—
RSU50,000$1,076,000—
PSU16,552$356,199—
RSU8,276$178,100—
RSU8,125$174,850—
RSU4,500$96,840—
RSU2,250$48,420—
RSU2,000$43,040—
PSU1,250$26,900—
Option16,644—$99.69
Option7,023—$128.67
Option8,430—$155.99

Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.

Sarepta Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Douglas IngramChief Executive Officer$7,840,666
Louise Rodino-KlapacPresident, Research and Development and Technical Operations$4,456,270
Ian Estepan · this pagePresident, Chief Operating Officer$4,444,392
Cristin RothfussExecutive Vice President, General Counsel$4,233,623
Ryan WongExecutive Vice President, Chief Financial Officer$3,211,867
Dallan MurrayFormer Executive Vice President, Chief Customer Officer$2,742,790

Ian Estepan's compensation dossier, Sarepta Therapeutics

You have read Ian Estepan's totals and holdings. The dossier adds each equity grant Sarepta Therapeutics disclosed for Ian Estepan and Sarepta Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Sarepta Therapeutics compensation record

free company brief

This page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Sarepta Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Sarepta Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order SRPT

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Ian Estepan's compensation dossier